SAO PAULO (Reuters) -Brazilian drugmaker Hypera plans to launch next year a generic version of semaglutide, the active ...

A new study suggests that restoring the pleasure of eating – not suppressing it – may help people eat more intentionally and ...

A new study links semaglutide, the active ingredient in Ozempic and Wegovy, to a higher risk of hair loss, especially in ...

The FDA recently approved the first treatment in nearly 30 years for acute stroke, and the agency also approved a novel drug ...

What goes up can come down. Investors who jumped on the Hims & Hers Health (NYSE: HIMS) bandwagon have experienced this pain ...

JM Financial is bullish on Mounjaro's success in India, citing its price advantage, higher efficiency and the country's large ...

Semaglutide, an active ingredient in drugs like Ozempic and Wegovy, is owned and produced by Novo Nordisk and is set to go ...

Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.

While the number of prescription fills for GLP-1 receptor agonists has continued to increase, health Insurance coverage for ...

SAO PAULO, March 21 (Reuters) - Brazilian drugmaker Hypera (HYPE3.SA), opens new tab plans to launch next year a generic version of semaglutide, the active ingredient of Novo Nordisk's (NOVOb.CO ...